Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRL-101 MAD study in healthy participants
NCT06532396Phase 1Completed
- Sponsor
- QurAlis
- Start
- Jul 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) and epilepsy comparing QRL-101 with Placebo (2 arms). Primary endpoint: Number of participants with one or more treatment emergent adverse events and serious adverse events at Day 10. Started Jul 2024; status: completed.
02
Drugs
QRL-101
03
Conditions
amyotrophic lateral sclerosis (ALS)epilepsy
Beyond the preview
Go deeper on NCT06532396.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06532396.